VKH
KERX

Virtu KCG Holdings’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Virtu KCG Holdings’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$82K Buy
+11,335
New +$70.8K ﹤0.01% 2471
2017
Q1 		– Sell
-23,870
Closed -$140K – 4063
2016
Q4 		$140K Sell
23,870
-15,079
-39% -$82.4K ﹤0.01% 2781
2016
Q3 		$207K Buy
+38,949
New +$210K ﹤0.01% 2332
2016
Q2 		– Sell
-85,452
Closed -$399K – 3527
2016
Q1 		$399K Buy
85,452
+32,818
+62% +$131K 0.01% 1426
2015
Q4 		$266K Buy
52,634
+39,883
+313% +$189K ﹤0.01% 2317
2015
Q3 		$45K Sell
12,751
-8,570
-40% -$57.4K ﹤0.01% 3012
2015
Q2 		$213K Sell
21,321
-2,115
-9% -$22.7K ﹤0.01% 2509
2015
Q1 		$298K Buy
23,436
+5,791
+33% +$74.4K 0.01% 1929
2014
Q4 		$250K Buy
+17,645
New +$273K ﹤0.01% 2587
2014
Q3 		– Sell
-17,580
Closed -$270K – 4307
2014
Q2 		$270K Buy
+17,580
New +$249K ﹤0.01% 2697
2013
Q4 		– Sell
-37,126
Closed -$375K – 4435
2013
Q3 		$375K Buy
+37,126
New +$330K ﹤0.01% 2355

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Virtu KCG Holdings's KERX Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in Keryx Biopharmaceuticals Inc (KERX) in Q2 2017: 11,335 shares worth $82K. The stake represents ﹤0.01% of the portfolio and ranks #2471 among its holdings. This is a return to the name: Virtu KCG Holdings previously reported a position in KERX as recently as Q4 2016.

Virtu KCG Holdings first reported a position in KERX in Q3 2013 and has held it in 11 quarters since. The position peaked at $399K in Q1 2016. 126 funds tracked by Wall St. Rank hold KERX as of Q2 2017.

  • Virtu KCG Holdings held 11,335 shares of Keryx Biopharmaceuticals Inc worth $82K as of Q2 2017.
  • Keryx Biopharmaceuticals Inc was a new Virtu KCG Holdings position in Q2 2017.
  • Keryx Biopharmaceuticals Inc made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2471 holding.
  • Virtu KCG Holdings first reported a position in Keryx Biopharmaceuticals Inc in Q3 2013 and has held it in 11 quarters since.
  • Virtu KCG Holdings's Keryx Biopharmaceuticals Inc position peaked at $399K in Q1 2016.
  • 126 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.